Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema
NCT: NCT06837480 · RECRUITING
Brief Summary
The U.S. Food and Drug Administration approved photobiomodulation therapy (PBMT) as a treatment for breast cancer-related arm lymphedema (BCRL) in 2006. The investigators conducted two pilot clinical trials. Results demonstrated the feasibility, acceptability, and preliminary efficacy of PBMT for the treatment of chronic lymphedema in head and neck cancer (HNC) survivors. The objective of this study is to further investigate and confirm the positive effects of PBMT on HNC-related chronic lymphedema.
Frequently Asked Questions
What is Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema?
Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema is a clinical trial registered under NCT06837480. Current status: RECRUITING.
What is the status of NCT06837480?
The current status of NCT06837480 (Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema) is: RECRUITING.
When did Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema start?
Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema started on 2026-01-15.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.